Dyslipidemia

Variations in apoB concentration among Hispanic or Latino populations could provide important implications for apoB use in cardiovascular risk assessment.

Higher levels of small-particle HDL were linked with greater gray matter volume and higher cognitive capacity among middle-aged adults.

This listicle highlights 5 major approvals and 5 trial updates in cardiovascular care from 2024.

To celebrate the close of 2024, we surveyed top cardiologist on what they view as the biggest storyline in their field from the past year.

Glycemic control continues to be a major risk factor for diabetic retinopathy, while overweight, obesity, and hypertension are growing in prevalence.

A study indicates that dyslipidemia may be associated with a greater risk of psoriasis development.

Tirzepatide's approval marks the first and only prescription medicine available for adults with moderate-to-severe obstructive sleep apnea and obesity.

A study finds that individuals with low or high LDL cholesterol levels face a greater cardiovascular risk than those with medium levels.

CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Olezarsen ushers in a new era of care as the first therapy to receive FDA approval for adults with familial chylomicronemia syndrome as an adjunct to diet.

Submission of the Biologics License Application seeks approval of lerodalcibep to lower LDL-C in patients with or at risk for ASCVD and primary hyperlipidemia.

Nathan D. Wong, MPH, PhD discusses the evolution of Lp(a) in risk assessment, given its role as a genetic risk factor for cardiovascular complications.

Our Cardiology Month in Review for November 2024 spotlights the approval of acoramidis and top content from AHA 2024.

Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

Laura Ross, PA-C, shares insights from the inaugural CAPP meeting on how lifestyle medicine and targeted therapies are transforming cardiovascular care.

Past APAC President Viet Le shares insights from CAPP 2024 on managing high-risk ASCVD, new non-statin therapies, and options for statin-intolerant patients.

A 6-year longitudinal study, involving more than 200,000 adults, reported a notable rise in dyslipidemia incidence during the COVID-19 pandemic.

A study found that adding depression to Life's Essential 8 provides minimal improvements in predicting cardiovascular and all-cause mortality risk.

A new meta-analysis found elevated triglyceride levels in patients with major depressive disorder, potentially explaining the link between depression and cardiovascular risks.

A new AHA statement highlights the benefits of lipoprotein apheresis for familial hypercholesterolemia and urges broader access to the underutilized therapy.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Rahul Aggarwal, MD, discusses how the VICTORION-1 PREVENT trial eligibility criteria apply to the general US population.